Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study

Nivolumab has shown durable response and safety in patients with hepatocellular carcinoma (HCC) in previous trials. However, real-world data of nivolumab in HCC patients, especially those with Child–Pugh class B, are limited. To investigate the effectiveness and safety of nivolumab in a real-world c...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Won-Mook, Lee, Danbi, Shim, Ju Hyun, Kim, Kang Mo, Lim, Young-Suk, Lee, Han Chu, Yoo, Changhoon, Park, Sook Ryun, Ryu, Min-Hee, Ryoo, Baek-Yeol, Choi, Jonggi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409289/
https://www.ncbi.nlm.nih.gov/pubmed/32698355
http://dx.doi.org/10.3390/cancers12071968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409289/
https://www.ncbi.nlm.nih.gov/pubmed/32698355
http://dx.doi.org/10.3390/cancers12071968

Ejemplares similares